BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Will AstraZeneca PLC (AZN) Bid for Amarin Corporation PLC (AMRN)? Rumors Swirl


10/24/2012 8:04:08 AM

AstraZeneca's new boss Pascal Soriot didn’t mess about when on his first day in the job he announced the suspension of the drugs group’s £2.8bn share buy-back program. Shareholders were obviously miffed, but analysts took it as a definite sign that he wanted to save the cash for earnings enhancing acquisitions. Soriot recently spent up to £169m on the rights to an experimental kidney drug, but rumours now suggest he has something much bigger up his sleeve. AZ’s shares shed 38p to 2900p ahead of tomorrow’s third-quarter trading statement. The fall was accompanied by speculation Soriot is planning to launch a cash bid for US biopharmaceutical group Amarin, whose shares moved against the trend on Wall Street yesterday with an early gain to $11.61.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->